Previous 10 | Next 10 |
home / stock / fgen / fgen articles
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced it will host Part I of a virtual KOL investor even...
As of Feb. 2, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in the...
A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independenc...
SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce its third quarter 2023 financial results on Monday, ...
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 89.5% to $2.7852 after the company reported outcomes from a UroShield study conducted at t...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Wednesday. The Dow traded up 0.14% to 34,9...
U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Wednesday. The Dow traded up 0.44% to 35,006.93 while the N...
Gainers AgileThought, Inc. (NASDAQ: AGIL) rose 96.5% to $0.3046 in pre-market trading after falling 17% on Tuesday. Digital Brands Group, Inc. (N...
Tuesday, FibroGen Inc (NASDAQ: FGEN) announced topline data from the Phase 3 LELANTOS-2 trial of pamrevlumab for ambulatory patients with...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...